Literature DB >> 27127135

The Involvement of PDGF-B/PDGFRβ Axis in the Resistance to Antiangiogenic and Antivascular Therapy in Renal Cancer.

Alin Adrian Cumpănas1, Anca Maria Cimpean2, Ovidiu Ferician1, Raluca Amalia Ceausu3, Simona Sarb3, Vlad Barbos3, Alice Dema4, Marius Raica3.   

Abstract

BACKGROUND/AIM: Studies developed in the field of platelet-derived growth factors/platelet-derived growth factor receptors (PDGFs/PDGFRs) inhibition have focused on the therapeutic effects on tumor cells, neglecting their potential effects on tumor blood vessels. We herein propose a differential and critic assessment of platelet-derived growth factor B (PDGF-B) and platelet-derived growth factor receptor β (PDGFRβ) in renal cell carcinoma, correlated with the four main vascular patterns previously reported by our team.
MATERIALS AND METHODS: PDGF-B and PDGFRβ were evaluated on 50 archival paraffin embedded specimens related to vascular endothelial growth factor (VEGF), its inhibitory isoform VEGF165b and vascular patterns. RESULTS AND
CONCLUSION: Our results support the involvement of VEGF165b in the phosphorylation of PDGFRβ with an inhibitory effect on endothelial proliferation and migration. The simultaneous action of PDGF-B/PDGFRβ and VEGF165b on the same type of receptor may explain the resistance to antiangiogenic therapy, which depends on the degree of modulation of PDGFRβ phosphorylation. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  PDGF-B; PDGFRβ; kidney cancer; tumor angiogenesis

Mesh:

Substances:

Year:  2016        PMID: 27127135

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Heterogeneity of Platelet Derived Growth Factor Pathway Gene Expression Profile Defines Three Distinct Subgroups of Renal Cell Carcinomas.

Authors:  Adela Maria Ferician; Ovidiu Catalin Ferician; Andrei Dragos Cumpanas; Patricia Lorena Berzava; Alexandru Nesiu; Ariana Barmayoun; Anca Maria Cimpean
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

2.  Design, construction and in vivo functional assessment of a hinge truncated sFLT01.

Authors:  Fahimeh Zakeri; Hamid Latifi-Navid; Zahra-Soheila Soheili; Mehdi Sadeghi; Seyed Shahriar Arab; Shahram Samiei; Ehsan Ranaei Pirmardan; Sepideh Taghizadeh; Hamid Ahmadieh; Ali Hafezi-Moghadam
Journal:  Gene Ther       Date:  2022-09-16       Impact factor: 4.184

3.  The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.

Authors:  Aristotelis Bamias; Vasilios Karavasilis; Nikolaos Gavalas; Kimon Tzannis; Epaminontas Samantas; Gerasimos Aravantinos; Angelos Koutras; Ioannis Gkerzelis; Euthymios Kostouros; Konstantinos Koutsoukos; Flora Zagouri; George Fountzilas; Meletios-Athanasios Dimopoulos
Journal:  Int J Clin Oncol       Date:  2018-10-29       Impact factor: 3.402

Review 4.  Cellular crosstalk of glomerular endothelial cells and podocytes in diabetic kidney disease.

Authors:  Shan Jiang; Manyu Luo; Xue Bai; Ping Nie; Yuexin Zhu; Hangxi Cai; Bing Li; Ping Luo
Journal:  J Cell Commun Signal       Date:  2022-01-18       Impact factor: 5.908

5.  VEGF-A165 b protects against proteinuria in a mouse model with progressive depletion of all endogenous VEGF-A splice isoforms from the kidney.

Authors:  Megan Stevens; Christopher R Neal; Andrew H J Salmon; David O Bates; Steven J Harper; Sebastian Oltean
Journal:  J Physiol       Date:  2017-07-03       Impact factor: 5.182

6.  Expression of growth factors and their receptors in the primary renal cell carcinoma: new data and review.

Authors:  Maria Volkova; Ilya Tsimafeyeu; Anna Olshanskaya; Yulia Khochenkova; Elyso Solomko; Saida Ashuba; Dmitry Khochenkov; Vsevolod Matveev
Journal:  Cent European J Urol       Date:  2020-12-09

7.  Growth factors contribute to the mediation of angiogenic capacity of glioma-associated mesenchymal stem cells.

Authors:  Qing Zhang; Wei Xiang; Bing-Zhou Xue; Dong-Ye Yi; Hong-Yang Zhao; Peng Fu
Journal:  Oncol Lett       Date:  2021-01-19       Impact factor: 2.967

8.  Inhibition of platelet-derived growth factor receptor synergistically increases the pharmacological effect of tamoxifen in estrogen receptor α positive breast cancer.

Authors:  Sangmin Kim; Daeun You; Yisun Jeong; Sun Young Yoon; Sung A Kim; Jeong Eon Lee
Journal:  Oncol Lett       Date:  2021-02-17       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.